A Comprehensive Toxicological Safety Evaluation of Anaerostipes caccae

Vickie Modica1, Róbert Glávits2, Amy Clewell1

  • 1AIBMR Life Sciences, Inc., Seattle, WA, USA.

Insights

Anaerostipes caccae CLB101, a butyrate-producing bacterium, was evaluated for safety. Studies found no genotoxicity or adverse effects in rats, establishing a No Observed Adverse Effect Level (NOAEL) for human consumption potential.

Area of Science:

  • Microbiology and Toxicology
  • Gut Microbiome Research

Background:

  • Anaerostipes caccae CLB101 is an anaerobic bacterium isolated from infant stool.
  • It produces butyrate and may promote microbiome health.
  • No prior toxicity data exists for A. caccae strains.

Purpose of the Study:

  • To assess the genotoxic and general toxicological potential of A. caccae CLB101.
  • To determine safety for potential human consumption.

Main Methods:

  • Genotoxicity assessed using in vivo comet and micronucleus assays due to anaerobic nature.
  • A 90-day repeated-dose oral toxicity study in Wistar rats (0-1000 mg/kg bw/day).
  • Evaluations included clinical signs, body weight, food consumption, clinical pathology, organ weights, and histopathology.

Main Results:

  • No evidence of clastogenicity or aneugenicity was found in genotoxicity assays.
  • No adverse effects were observed in rats across all tested doses in the 90-day study.
  • A No Observed Adverse Effect Level (NOAEL) of 1000 mg/kg bw/day (1.9 × 10^11 CFU/kg bw/day) was established.

Conclusions:

  • Anaerostipes caccae CLB101 demonstrates no genotoxic or significant toxicological concerns.
  • The study supports the potential safety of A. caccae CLB101 for human consumption.
  • A high NOAEL indicates a favorable safety profile for this probiotic candidate.